Indication for symptomatic VMA

ThromboGenics has announced that the US Food and Drug Administration (FDA) has approved JETREAR (ocriplasmin) in the US for the treatment of symptomatic VMA. Dr Patrik De Haes, CEO of ThromboGenics, said: “The FDA approval of JETREAR is a major milestone for the company. We are extremely pleased that we will be able to meet a major unmet clinical need in ophthalmology when we make JETREAR, the first pharmacological agent for symptomatic VMA, available to the many thousands of US patients who could benefit from treatment of this progressive, sight-threatening condition. We are continuing to prepare for the planned launch of JETREAR in January 2013 through our own US commercial organisation. This is the biggest step in transforming ThromboGenics into a profitable biopharmaceutical company developing and commercialising innovative ophthalmic medicines,†said Dr De Haes.  

•  www.thrombogenics.com